Table 2.
Most significant diseases and function affected in AKT-NRASG12V and AKT-NRASG12V+DDC tumors
| Tumor group | p-value |
|---|---|
| Shared pathways | |
| AKT-NRASG12V | |
| Cellular Growth and Proliferation | 4.73E-22 - 4.11E-04 |
| Cell Death and Survival | 1.51E-16 - 6.42E04 |
| Cardiovascular System Development and Function | 2.17E-15 - 6.42E-04 |
| Cancer | 3.19E-14 - 6.16E04 |
| AKT-NRASG12V+DDC | |
| Cellular Growth and Proliferation | 4.17E-30 - 4.02E-05 |
| Cell Death and Survival | 8.54E-29 - 5.3E-05 |
| Cancer | 4.66E-21 - 5.14E-05 |
| Cardiovascular System Development and Function | 1.44E-18 - 4.21E-05 |
| Unique pathways | |
| AKT-NRASG12V | |
| Organismal Survival | 5.95E-17 - 1.83E-04 |
| AKT-NRASG12V+DDC | |
| Organismal Injury and Abnormalities | 4.66E-21 - 5.2E-05 |